ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,593Medicare Part D Prescriptions Filled, Including Refills

Rank: 177 out of 2604

$471K Total Retail Price of All Prescriptions

Rank: 255 out of 2604

726 Patients Receiving at Least One Drug in Part D
80%Patients 65 Years and Older
17% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Michigan
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 726 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

15% of this provider’s 726 patients filled at least one prescription for a schedule three drug, compared to an average of 16%.

Risky Drugs to Seniors

1% of this provider’s 7,089 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$55 was the average price of a prescription from this provider, compared to $61 among peers.

Prescriptions per Patient

12 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Michigan
LEVOTHYROXINE SODIUM 473 401 1 4
SIMVASTATIN 411 345 2 2
HYDROCODONE-ACETAMINOPHEN 325 195 S3 3 1
OMEPRAZOLE 297 241 4 5
LISINOPRIL 226 204 5 3
LISINOPRIL-HYDROCHLOROTHIAZIDE 210 179 6 22
AMLODIPINE BESYLATE 201 194 7 6
ATENOLOL 183 170 8 11
TRAMADOL HCL 170 134 9 15
METFORMIN HCL 152 141 10 7
HYDROCHLOROTHIAZIDE 144 143 11 10
ZOLPIDEM TARTRATE 135 130 12 21
FUROSEMIDE 133 110 13 8
LOSARTAN POTASSIUM 127 115 14 20
CITALOPRAM HBR 118 97 15 18
METFORMIN HCL ER 113 103 16 72
LANTUS SOLOSTAR 108 102 17 84
FLUTICASONE PROPIONATE 106 78 18 31
METOPROLOL TARTRATE 103 96 19 9
LOSARTAN-HYDROCHLOROTHIAZIDE 103 95 19 77
LOVASTATIN 103 95 19 24
PRAVASTATIN SODIUM 101 97 22 14
GABAPENTIN 100 84 23 12
ATORVASTATIN CALCIUM 94 82 24 19
METOPROLOL SUCCINATE 90 81 25 17
AZITHROMYCIN 89 72 26 33
GLIMEPIRIDE 87 74 27 57
TRIAMTERENE-HCTZ 85 81 28 55
POTASSIUM CHLORIDE 84 73 29 16
MELOXICAM 82 77 30 36
TERAZOSIN HCL 72 72 31 129
NABUMETONE 67 53 32 197
ALENDRONATE SODIUM 67 61 32 29
LANSOPRAZOLE 64 53 34 137
SERTRALINE HCL 58 43 35 23
TAMSULOSIN HCL 56 56 36 30
WARFARIN SODIUM 56 50 36 13
ALPRAZOLAM 55 49 38 119
CARVEDILOL 54 48 39 26
TRIAMCINOLONE ACETONIDE 54 47 39 125
PANTOPRAZOLE SODIUM 54 52 39 64
CIPROFLOXACIN HCL 52 50 42 59
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 31, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.